Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. University Hospital of Siena, Siena, Italy



Survival: 7.0 months
   
Toxicity Grade: 4
   
Treatments: Immunotherapy
   
Drugs:
Country: Italy
   
City/State/Province: Siena
   
Hospital: University Hospital of Siena
   
Journal: Link
   
Date: 10/2013

Description:
Patients:
This study involved 74 pretreated advanced melanoma patients with a median age of 56 years, 62.2% of whom were male.

Treatment:
Patients were treated with the immune therapy agent ipilimumab, which is an antibody to the CTLA-4 protein and enhances the immune response against cancer cells.

Toxicities:
The most severe toxicities were grade 4 pancytopenia (decreased number of blood cells numbers). Grade 3 diarrhea and pain were also reported.

Results:
The median overall survival was 7.0 months.

Support:
This study was partially funded by Bristol Myers Squibb, makers of ipilimumab.

Correspondence: Dr. Michele Maio; email: mmaiocro@gmail.com

E-mail to a Friend Email Physician More Information